

SUBSTITUTE FORM PTO-1390 (REV. 04-2004)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER H1089/20016	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/510172	
INTERNATIONAL APPLICATION NO. PCT/IN03/00135		INTERNATIONAL FILING DATE April 2, 2003 (04-02-2003)		PRIORITY DATE CLAIMED April 2, 2003 (04-02-2004)	
TITLE OF INVENTION		NOVEL CRYSTALLINE FORMS OF GATIFLOXACIN			
APPLICANT(S) FOR DO/EO/US		Reddy Bandi PARTHASARADHI, Reddy Kura RATHNAKAR, Reddy Rapolu RAJI, Reddy Dasari MURALIDHARA and Reddy Meghi RAVIKANTH			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input checked="" type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 					
Items 11 to 20 below concern document(s) or information included:					
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 & 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: PCT Request form with Declaration, Application Data Sheet, return receipt postcard, Express Mailing transmittal sheet no. EL962209306US 					

U.S. APPLICATION NO. (If known, see 37 CFR 1.40) 10/510172		INTERNATIONAL APPLICATION NO. PCT/IN03/001365		ATTORNEY'S DOCKET NO. H1089/20016	
----------------------------------------------------------------------	--	--------------------------------------------------	--	--------------------------------------	--

21. <input type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1080.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$920.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$770.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$730.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =	CALCULATIONS PTO USE ONLY																										
	\$1,080																										
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	\$																										
<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:20%;">CLAIMS</th> <th style="width:20%;">NUMBER FILED</th> <th style="width:20%;">NUMBER EXTRA</th> <th style="width:20%;">RATE</th> <th style="width:20%;">\$</th> </tr> <tr> <td>Total claims</td> <td>35 - 20 =</td> <td>15</td> <td>x \$18.00</td> <td>\$ 270</td> </tr> <tr> <td>Independent claims</td> <td>5 - 3 =</td> <td>2</td> <td>x \$86.00</td> <td>\$ 172</td> </tr> <tr> <td colspan="3">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ 290.00</td> <td>\$</td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$1,522</td> </tr> </table>	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	Total claims	35 - 20 =	15	x \$18.00	\$ 270	Independent claims	5 - 3 =	2	x \$86.00	\$ 172	MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ 290.00	\$	TOTAL OF ABOVE CALCULATIONS =				\$1,522		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$																							
Total claims	35 - 20 =	15	x \$18.00	\$ 270																							
Independent claims	5 - 3 =	2	x \$86.00	\$ 172																							
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ 290.00	\$																							
TOTAL OF ABOVE CALCULATIONS =				\$1,522																							
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.	\$																										
SUBTOTAL =	\$ 761																										
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).	\$																										
TOTAL NATIONAL FEE =	\$																										
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property \$ +	\$																										
TOTAL FEES ENCLOSED =	\$ 761																										
	Amt. to be refunded:	\$																									
	Amt to be charged:	\$																									

a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 03-0075 in the amount of \$ 761 to cover the above fees.
 A duplicate copy of this sheet is enclosed. ☒ The Commissioner is hereby authorized to charge any additional fees
which may be required, or credit any overpayment to Deposit Account
03-0075. A duplicate copy of this sheet is enclosed.

c. ☐ Fees are to be charged to a credit card. **WARNING: Information on this form may become public. Credit card information**
should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Customer No. 03000

	SIGNATURE
	Robert S. Silver
	NAME
	35,681
	REGISTRATION NUMBER

Attny Docket No. H1089/20016,
PTO Customer No. 03000

Applicant : Reddy Bandi PARTHASARADHI et al.

Title : NOVEL CRYSTALLINE FORMS OF GATIFLOXACIN

The following documents are submitted for the above-identified invention for entry into the U.S. National stage under 35 U.S.C. §371, based on the International Application No. PCT/IN03/00135, which includes the following:

1. One (1) sheet of Transmittal Letter;
2. Calculation sheet, in duplicate;
3. Application Data Sheet;
4. Preliminary Amendment;
5. PCT Request form with Declaration;
6. Copy PCT Application, as filed with 6 pages Description, 4 pages Claims, 1 page Abstract, and 5 sheet Drawings; and
7. Return Receipt Post Card.

"Express Mail" Mailing Label No. EL 962 209 306 US
Date of Deposit October 4, 2004

I hereby certify that the above-identified documents are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,

Day Karlo


